Experimental Pfizer breast cancer drug designated a ‘breakthrough’

TRENTON, N.J. — Pfizer Inc. said Wednesday that its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.

 Afficher le reportage au complet